Concepts (230)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brachytherapy | 11 | 2026 | 139 | 2.620 |
Why?
|
| Uterine Cervical Neoplasms | 11 | 2025 | 325 | 2.550 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 11 | 2020 | 216 | 1.390 |
Why?
|
| Endometrial Neoplasms | 4 | 2025 | 242 | 1.360 |
Why?
|
| Genital Neoplasms, Female | 3 | 2025 | 118 | 1.120 |
Why?
|
| Chemoradiotherapy | 5 | 2020 | 338 | 1.010 |
Why?
|
| Breast Neoplasms | 15 | 2021 | 3285 | 0.990 |
Why?
|
| Radiotherapy Dosage | 10 | 2025 | 479 | 0.820 |
Why?
|
| Radiation Oncology | 5 | 2026 | 130 | 0.800 |
Why?
|
| Radiation Injuries | 5 | 2021 | 160 | 0.760 |
Why?
|
| Radiosurgery | 3 | 2025 | 352 | 0.670 |
Why?
|
| Vaccines, DNA | 1 | 2020 | 20 | 0.620 |
Why?
|
| Human papillomavirus 18 | 1 | 2020 | 22 | 0.620 |
Why?
|
| Human papillomavirus 16 | 1 | 2020 | 46 | 0.610 |
Why?
|
| Cell Hypoxia | 1 | 2020 | 191 | 0.590 |
Why?
|
| Safety | 1 | 2020 | 138 | 0.590 |
Why?
|
| Radiotherapy, Intensity-Modulated | 6 | 2025 | 200 | 0.580 |
Why?
|
| Radiotherapy | 3 | 2016 | 325 | 0.550 |
Why?
|
| Radiometry | 2 | 2016 | 64 | 0.520 |
Why?
|
| Female | 44 | 2025 | 51761 | 0.480 |
Why?
|
| Cone-Beam Computed Tomography | 3 | 2020 | 79 | 0.440 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 314 | 0.390 |
Why?
|
| Radiotherapy, Conformal | 4 | 2020 | 88 | 0.380 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 1214 | 0.380 |
Why?
|
| Humans | 49 | 2026 | 98370 | 0.370 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2018 | 1107 | 0.370 |
Why?
|
| Middle Aged | 27 | 2025 | 29532 | 0.350 |
Why?
|
| Aged, 80 and over | 14 | 2025 | 7418 | 0.350 |
Why?
|
| Radiography, Thoracic | 1 | 2014 | 331 | 0.350 |
Why?
|
| Aged | 23 | 2025 | 21844 | 0.340 |
Why?
|
| Lymph Nodes | 2 | 2016 | 563 | 0.330 |
Why?
|
| Mastectomy, Segmental | 3 | 2011 | 115 | 0.330 |
Why?
|
| Radiation Dosage | 3 | 2025 | 232 | 0.310 |
Why?
|
| Adult | 21 | 2025 | 29587 | 0.290 |
Why?
|
| Neoplasm Staging | 9 | 2021 | 2085 | 0.290 |
Why?
|
| Radiation Tolerance | 1 | 2010 | 179 | 0.290 |
Why?
|
| Skin | 3 | 2024 | 591 | 0.290 |
Why?
|
| Dietary Supplements | 1 | 2010 | 152 | 0.280 |
Why?
|
| Sexism | 2 | 2019 | 64 | 0.280 |
Why?
|
| Oxygen | 2 | 2026 | 773 | 0.270 |
Why?
|
| Biological Products | 1 | 2010 | 190 | 0.260 |
Why?
|
| Prostheses and Implants | 1 | 2007 | 130 | 0.250 |
Why?
|
| Treatment Outcome | 11 | 2025 | 9770 | 0.240 |
Why?
|
| Radiobiology | 1 | 2026 | 15 | 0.240 |
Why?
|
| Bone and Bones | 1 | 2007 | 272 | 0.240 |
Why?
|
| Prostate | 1 | 2010 | 434 | 0.240 |
Why?
|
| Proton Therapy | 1 | 2025 | 44 | 0.220 |
Why?
|
| Organs at Risk | 2 | 2016 | 56 | 0.220 |
Why?
|
| Retrospective Studies | 11 | 2025 | 11043 | 0.220 |
Why?
|
| Prostatic Neoplasms | 2 | 2021 | 1842 | 0.220 |
Why?
|
| Cisplatin | 3 | 2018 | 578 | 0.210 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2024 | 31 | 0.210 |
Why?
|
| Nocebo Effect | 1 | 2024 | 5 | 0.210 |
Why?
|
| Radiation, Ionizing | 1 | 2024 | 123 | 0.210 |
Why?
|
| Drugs, Generic | 1 | 2024 | 21 | 0.210 |
Why?
|
| Mammography | 1 | 2007 | 504 | 0.200 |
Why?
|
| Dysbiosis | 1 | 2024 | 103 | 0.200 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2021 | 326 | 0.190 |
Why?
|
| Tumor Burden | 2 | 2017 | 331 | 0.190 |
Why?
|
| Mental Health | 1 | 2024 | 219 | 0.180 |
Why?
|
| Heart | 3 | 2018 | 527 | 0.180 |
Why?
|
| Anxiety | 1 | 2024 | 370 | 0.170 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2021 | 66 | 0.170 |
Why?
|
| Hysterectomy | 2 | 2020 | 174 | 0.160 |
Why?
|
| Rectum | 3 | 2016 | 152 | 0.160 |
Why?
|
| Young Adult | 7 | 2024 | 7568 | 0.160 |
Why?
|
| Standard of Care | 1 | 2021 | 71 | 0.160 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2020 | 31 | 0.160 |
Why?
|
| Neoplasms | 2 | 2026 | 3349 | 0.160 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2020 | 34 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 2661 | 0.150 |
Why?
|
| Carcinoma, Endometrioid | 2 | 2019 | 60 | 0.150 |
Why?
|
| Oximetry | 1 | 2020 | 90 | 0.150 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 1178 | 0.150 |
Why?
|
| Depression | 1 | 2024 | 619 | 0.150 |
Why?
|
| Multimodal Imaging | 1 | 2020 | 115 | 0.150 |
Why?
|
| Dilatation | 1 | 2019 | 47 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2020 | 2678 | 0.150 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 383 | 0.140 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 520 | 0.140 |
Why?
|
| Microbiota | 1 | 2024 | 472 | 0.140 |
Why?
|
| Breast | 2 | 2011 | 316 | 0.140 |
Why?
|
| Constriction, Pathologic | 1 | 2019 | 212 | 0.140 |
Why?
|
| Urethral Neoplasms | 1 | 2018 | 10 | 0.140 |
Why?
|
| Physicians, Women | 1 | 2019 | 66 | 0.140 |
Why?
|
| Breath Holding | 1 | 2018 | 26 | 0.140 |
Why?
|
| Postoperative Care | 2 | 2017 | 237 | 0.140 |
Why?
|
| Methylprednisolone | 1 | 2018 | 65 | 0.140 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 354 | 0.130 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2018 | 34 | 0.130 |
Why?
|
| Vagina | 1 | 2019 | 187 | 0.130 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2020 | 304 | 0.130 |
Why?
|
| Thoracic Wall | 2 | 2014 | 27 | 0.130 |
Why?
|
| Deoxycytidine | 1 | 2018 | 218 | 0.130 |
Why?
|
| Colon, Sigmoid | 1 | 2016 | 7 | 0.130 |
Why?
|
| Polycythemia Vera | 1 | 2016 | 22 | 0.120 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2018 | 158 | 0.120 |
Why?
|
| Urinary Bladder | 2 | 2016 | 262 | 0.120 |
Why?
|
| Drug Substitution | 1 | 2016 | 30 | 0.120 |
Why?
|
| Repressor Proteins | 1 | 2020 | 449 | 0.120 |
Why?
|
| Hydroxyurea | 1 | 2016 | 233 | 0.120 |
Why?
|
| Hyperlipidemias | 1 | 2016 | 93 | 0.120 |
Why?
|
| Patient Care Planning | 1 | 2016 | 92 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 977 | 0.120 |
Why?
|
| Pyrazoles | 1 | 2016 | 160 | 0.110 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 2471 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 663 | 0.110 |
Why?
|
| Lung | 2 | 2014 | 1408 | 0.110 |
Why?
|
| Contrast Media | 1 | 2020 | 1013 | 0.110 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 425 | 0.110 |
Why?
|
| Radiotherapy Setup Errors | 1 | 2014 | 2 | 0.110 |
Why?
|
| Hematologic Diseases | 1 | 2015 | 77 | 0.110 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 1752 | 0.110 |
Why?
|
| United States | 5 | 2021 | 8262 | 0.100 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 1268 | 0.100 |
Why?
|
| Patient Positioning | 1 | 2014 | 68 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1539 | 0.100 |
Why?
|
| Databases, Factual | 2 | 2021 | 1100 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2015 | 305 | 0.100 |
Why?
|
| Male | 13 | 2024 | 47263 | 0.100 |
Why?
|
| Disease-Free Survival | 2 | 2013 | 1195 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 1 | 2014 | 311 | 0.090 |
Why?
|
| Equipment Design | 1 | 2014 | 425 | 0.090 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 406 | 0.090 |
Why?
|
| Hodgkin Disease | 1 | 2013 | 144 | 0.090 |
Why?
|
| Feasibility Studies | 3 | 2026 | 817 | 0.090 |
Why?
|
| Surgical Instruments | 2 | 2014 | 70 | 0.090 |
Why?
|
| Radiodermatitis | 1 | 2011 | 10 | 0.090 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2012 | 100 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 682 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 1116 | 0.080 |
Why?
|
| Trigeminal Neuralgia | 1 | 2011 | 11 | 0.080 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2011 | 18 | 0.080 |
Why?
|
| Colony-Forming Units Assay | 1 | 2010 | 39 | 0.080 |
Why?
|
| Fatigue | 2 | 2024 | 187 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 907 | 0.080 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2010 | 171 | 0.080 |
Why?
|
| Clinical Protocols | 1 | 2010 | 156 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 1010 | 0.080 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 631 | 0.070 |
Why?
|
| Organ Specificity | 1 | 2010 | 287 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 843 | 0.070 |
Why?
|
| Time Factors | 2 | 2021 | 5577 | 0.070 |
Why?
|
| Obesity | 2 | 2014 | 1077 | 0.070 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2007 | 166 | 0.060 |
Why?
|
| Needles | 1 | 2026 | 43 | 0.060 |
Why?
|
| Epithelial Cells | 1 | 2010 | 710 | 0.060 |
Why?
|
| Adolescent | 4 | 2024 | 10140 | 0.060 |
Why?
|
| Cell Line | 1 | 2010 | 2483 | 0.060 |
Why?
|
| Cross Infection | 1 | 2007 | 155 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 2792 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2020 | 3612 | 0.060 |
Why?
|
| Tumor Hypoxia | 1 | 2026 | 53 | 0.060 |
Why?
|
| Wakefulness-Promoting Agents | 1 | 2024 | 1 | 0.050 |
Why?
|
| Placebo Effect | 1 | 2024 | 37 | 0.050 |
Why?
|
| Uncertainty | 1 | 2024 | 81 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2010 | 1791 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2024 | 270 | 0.050 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2026 | 340 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 2896 | 0.050 |
Why?
|
| Mastectomy | 2 | 2016 | 273 | 0.050 |
Why?
|
| Adaptation, Psychological | 1 | 2024 | 190 | 0.050 |
Why?
|
| Melphalan | 1 | 2023 | 98 | 0.050 |
Why?
|
| Vidarabine | 1 | 2023 | 107 | 0.050 |
Why?
|
| Prospective Studies | 4 | 2014 | 4818 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2018 | 1529 | 0.050 |
Why?
|
| Respiration | 2 | 2018 | 272 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 2017 | 0.040 |
Why?
|
| Child | 3 | 2024 | 7750 | 0.040 |
Why?
|
| Prone Position | 1 | 2020 | 62 | 0.040 |
Why?
|
| Bacteria | 1 | 2024 | 546 | 0.040 |
Why?
|
| Genomics | 1 | 2026 | 903 | 0.040 |
Why?
|
| Uterus | 1 | 2021 | 231 | 0.040 |
Why?
|
| Scandinavian and Nordic Countries | 1 | 2019 | 8 | 0.040 |
Why?
|
| Women's Rights | 1 | 2019 | 8 | 0.040 |
Why?
|
| Age Factors | 1 | 2024 | 1974 | 0.040 |
Why?
|
| Attention | 1 | 2024 | 435 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2024 | 638 | 0.040 |
Why?
|
| Workflow | 1 | 2020 | 86 | 0.040 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2019 | 32 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2014 | 867 | 0.040 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2019 | 69 | 0.040 |
Why?
|
| Spirometry | 1 | 2018 | 78 | 0.030 |
Why?
|
| Vincristine | 1 | 2018 | 102 | 0.030 |
Why?
|
| Survival Rate | 2 | 2013 | 2050 | 0.030 |
Why?
|
| Prednisone | 1 | 2018 | 251 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2018 | 284 | 0.030 |
Why?
|
| Faculty, Medical | 1 | 2019 | 194 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2018 | 285 | 0.030 |
Why?
|
| Kinetics | 1 | 2019 | 1477 | 0.030 |
Why?
|
| Risk Factors | 2 | 2019 | 6273 | 0.030 |
Why?
|
| Nitriles | 1 | 2016 | 171 | 0.030 |
Why?
|
| Pelvis | 1 | 2016 | 106 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 394 | 0.030 |
Why?
|
| Lymphatic Irradiation | 1 | 2014 | 7 | 0.030 |
Why?
|
| Rotation | 1 | 2014 | 95 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2013 | 4044 | 0.030 |
Why?
|
| Gene Rearrangement | 1 | 2015 | 175 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2016 | 415 | 0.030 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2014 | 135 | 0.020 |
Why?
|
| Acute Disease | 1 | 2015 | 860 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2013 | 4042 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2016 | 1790 | 0.020 |
Why?
|
| Chicago | 1 | 2016 | 1519 | 0.020 |
Why?
|
| Mice | 1 | 2026 | 12735 | 0.020 |
Why?
|
| Comorbidity | 1 | 2015 | 1035 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1296 | 0.020 |
Why?
|
| Organ Size | 1 | 2011 | 370 | 0.020 |
Why?
|
| Age Distribution | 1 | 2011 | 212 | 0.020 |
Why?
|
| Vinblastine | 1 | 2010 | 84 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 890 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 578 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1787 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 1945 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2010 | 221 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2019 | 1126 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2011 | 402 | 0.020 |
Why?
|
| Carboplatin | 1 | 2010 | 331 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2010 | 543 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2013 | 2009 | 0.020 |
Why?
|
| Quality of Life | 1 | 2016 | 1899 | 0.020 |
Why?
|
| Biomarkers | 1 | 2014 | 2021 | 0.020 |
Why?
|
| Esthetics | 1 | 2007 | 52 | 0.020 |
Why?
|
| Pakistan | 1 | 2007 | 18 | 0.020 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2007 | 89 | 0.010 |
Why?
|
| Animals | 1 | 2026 | 28981 | 0.010 |
Why?
|
| Movement | 1 | 2007 | 313 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 923 | 0.010 |
Why?
|
| Intensive Care Units | 1 | 2007 | 474 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 2381 | 0.010 |
Why?
|